31 found
Sort by:
  1. Gail E. Henderson & Nancy M. P. King (forthcoming). Studying Benefit in Gene Transfer Research. Irb.
    No categories
    Direct download (2 more)  
     
    My bibliography  
     
    Export citation  
  2. Nancy M. P. King (forthcoming). Perspective: The Stories We Tell Ourselves. Hastings Center Report.
    No categories
     
    My bibliography  
     
    Export citation  
  3. Nancy M. P. King (2013). There's A Lot We Don't Know (and We Ought to Say So). American Journal of Bioethics 13 (12):20-21.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  4. Nancy M. P. King & Richard Robeson (2013). Athletes Are Guinea Pigs. American Journal of Bioethics 13 (10):13 - 14.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  5. Leili Fatehi, Susan M. Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M. P. King, Efrosini Kokkoli, Gary Marchant, Andrew D. Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A. Siegel & Samuel Wickline (2012). Recommendations for Nanomedicine Human Subjects Research Oversight: An Evolutionary Approach for an Emerging Field. Journal of Law, Medicine and Ethics 40 (4):716-750.
    The nanomedicine field is fast evolving toward complex, “active,” and interactive formulations. Like many emerging technologies, nanomedicine raises questions of how human subjects research (HSR) should be conducted and the adequacy of current oversight, as well as how to integrate concerns over occupational, bystander, and environmental exposures. The history of oversight for HSR investigating emerging technologies is a patchwork quilt without systematic justification of when ordinary oversight for HSR is enough versus when added oversight is warranted. Nanomedicine HSR provides an (...)
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  6. Gail E. Henderson, Eric T. Juengst, Nancy M. P. King, Kristine Kuczynski & Marsha Michie (2012). What Research Ethics Should Learn From Genomics and Society Research: Lessons From the ELSI Congress of 2011. Journal of Law, Medicine and Ethics 40 (4):1008-1024.
    Research on the ethical, legal, and social implications (ELSI) of human genomics has devoted significant attention to the research ethics issues that arise from genomic science as it moves through the translational process. Given the prominence of these issues in today's debates over the state of research ethics overall, these studies are well positioned to contribute important data, contextual considerations, and policy arguments to the wider research ethics community's deliberations, and ultimately to develop a research ethics that can help guide (...)
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  7. James H. Jones & Nancy M. P. King (2012). Bad Blood Thirty Years Later: A Q&A with James H. Jones. Journal of Law, Medicine and Ethics 40 (4):867-872.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  8. Nancy M. P. King (2012). Nanomedicine First-in-Human Research: Challenges for Informed Consent. Journal of Law, Medicine and Ethics 40 (4):823-830.
    Risks of harm, translational uncertainty, ambiguities in potential direct benefit, and long-term follow-up merit consideration in first-in-human research. Some nanomedical technologies have additional characteristics that should be addressed, including: defining and describing nanomedical interventions; bystander risks; the therapeutic misconception; and a decision-making context that includes both common use of nanomaterials outside medicine and persistent unknowns about the effects of nanosize. This paper considers how to address these issues in informed consent to first-in-human nanomedicine research.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  9. Nancy M. P. King & Ana S. Iltis (2012). INTRODUCTION: Research Ethics: Reexamining Key Concerns. Journal of Law, Medicine and Ethics 40 (4):865-866.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  10. Nancy M. P. King & John C. Moskop (2012). Advance Care Planning and End-of-Life Decision-Making. In D. Micah Hester & Toby Schonfeld (eds.), Guidance for Healthcare Ethics Committees. Cambridge University Press.
     
    My bibliography  
     
    Export citation  
  11. Nancy M. P. King & Michael J. Hyde (eds.) (2011). Bioethics, Public Moral Argument, and Social Responsibility. Routledge.
    Bioethics, Public Moral Argument, and Social Responsibility explores the role of democratically oriented argument in promoting public understanding and discussion of the benefits and burdens of biotechnological progress. The contributors examine moral and policy controversies surrounding biomedical technologies and their place in American society, beginning with an examination of discourse and moral authority in democracy, and addressing a set of issues that include: dignity in health care; the social responsibilities of scientists, journalists, and scholars; and the language of genetics and (...)
     
    My bibliography  
     
    Export citation  
  12. Rebecca L. Walker & Nancy M. P. King (2011). Biodefense Research and the U.S. Regulatory Structure Whither Nonhuman Primate Moral Standing? Kennedy Institute of Ethics Journal 21 (3):277-310.
    Biodefense and emerging infectious disease animal research aims to avoid or ameliorate human disease, suffering, and death arising, or potentially arising, from natural outbreaks or intentional deployment of some of the world’s most dreaded pathogens. Top priority research goals include finding vaccines to prevent, diagnostic tools to detect, and medicines for smallpox, plague, ebola, anthrax, tularemia, and viral hemorrhagic fevers, among many other pathogens (National Institute of Allergy and Infectious Diseases [NIAID] priority pathogens). To this end, increased funding for conducting (...)
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  13. Robert M. Nelson, Nancy M. P. King & Ken Kipnis (2010). An Open Letter to Institutional Review Boards Considering Northfield Laboratories' PolyHeme® Trial. American Journal of Bioethics 10 (10):5-8.
    At the time of this writing, a widely publicized, waived-consent trial is underway. Sponsored by Northfield Laboratories, Inc. (Evanston, IL) the trial is intended to evaluate the emergency use of PolyHeme?, an oxygen-carrying resuscitative fluid that might prevent deaths from uncontrolled bleeding. The protocol allows patients in hemorrhagic shock to be randomized between PolyHeme? and saline in the field and, still without consent, randomized between PolyHeme? and blood after arrival at an emergency department. The Federal regulations that govern the waiver (...)
    Direct download (7 more)  
     
    My bibliography  
     
    Export citation  
  14. Nancy M. P. King (2009). Benefits, Harms, and Motives in Clinical Research. Hastings Center Report 39 (4):3-3.
    Direct download (6 more)  
     
    My bibliography  
     
    Export citation  
  15. Nancy M. P. King (2009). Reviews in Medical Ethics. Journal of Law, Medicine and Ethics 37 (1):147-148.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  16. Nancy M. P. King (2007). The Glass House : Assessing Bioethics. In Lisa A. Eckenwiler & Felicia Cohn (eds.), The Ethics of Bioethics: Mapping the Moral Landscape. Johns Hopkins University Press.
     
    My bibliography  
     
    Export citation  
  17. Nancy M. P. King & Richard Robeson (2007). Athlete or Guinea Pig? Sports and Enhancement Research. Studies in Ethics, Law, and Technology 1 (1).
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  18. Kathleen Cranley Glass, David B. Resnik, Stephen Olufemi Sodeke, Halley S. Faust, Rebecca Dresser, Nancy M. P. King, C. D. Herrera, David Orentlicher & Lynn A. Jansen (2006). Protection of Human Subjects and Scientific Progress: Can the Two Be Reconciled? Hastings Center Report 36 (1):4-9.
    Direct download (6 more)  
     
    My bibliography  
     
    Export citation  
  19. Ken Kipnis, Nancy M. P. King & Robert M. Nelson (2006). An Open Letter to Institutional Review Boards Considering Northfield Laboratories' Polyheme® Trial. American Journal of Bioethics 6 (3):18 – 21.
    At the time of this writing, a widely publicized, waived-consent trial is underway. Sponsored by Northfield Laboratories, Inc. (Evanston, IL) the trial is intended to evaluate the emergency use of PolyHeme®, an oxygen-carrying resuscitative fluid that might prevent deaths from uncontrolled bleeding. The protocol allows patients in hemorrhagic shock to be randomized between PolyHeme® and saline in the field and, still without consent, randomized between PolyHeme® and blood after arrival at an emergency department. The Federal regulations that govern the waiver (...)
    Direct download (7 more)  
     
    My bibliography  
     
    Export citation  
  20. Ken Kipnis, Nancy M. P. King & Robert M. Nelson (2006). Response to Open Peer Commentaries on “An Open Letter to Institutional Review Boards Considering Northfield Laboratories' PolyHeme® Trial”: The Emergency Exception and Unproven/Unsatisfactory Treatment. American Journal of Bioethics 6 (3).
    No categories
    Direct download  
     
    My bibliography  
     
    Export citation  
  21. Gail E. Henderson, Arlene M. Davis & Nancy M. P. King (2004). Vulnerability to Influence: A Two-Way Street. American Journal of Bioethics 4 (3):50 – 52.
    Direct download (5 more)  
     
    My bibliography  
     
    Export citation  
  22. Nancy M. P. King (2003). Accident & Desire: Inadvertent Germline Effects in Clinical Research. Hastings Center Report 33 (2):23-30.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  23. Nancy M. P. King (2003). The Stories We Tell Ourselves. Hastings Center Report 33 (5):48-48.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  24. Nancy M. P. King (2002). RAC Oversight of Gene Transfer Research: A Model Worth Extending? Journal of Law, Medicine and Ethics 30 (3):381-389.
    Direct download (3 more)  
     
    My bibliography  
     
    Export citation  
  25. Nancy M. P. King (2000). Defining and Describing Benefit Appropriately in Clinical Trials. Journal of Law, Medicine and Ethics 28 (4):332-343.
    Direct download (4 more)  
     
    My bibliography  
     
    Export citation  
  26. Nancy M. P. King (2000). Not for Distribution. Journal of Law, Medicine and Ethics 28:332-343.
     
    My bibliography  
     
    Export citation  
  27. Nancy M. P. King (1999). Who Ate the Apple? A Commentary on the Core Competencies Report. HEC Forum 11 (2):170-175.
    Direct download (6 more)  
     
    My bibliography  
     
    Export citation  
  28. Nancy M. P. King (1996). The Ethics Committee as Greek Chorus. HEC Forum 8 (6):346-354.
    Direct download (5 more)  
     
    My bibliography  
     
    Export citation  
  29. Nancy M. P. King (1995). Experimental Treatment Oxymoron or Aspiration? Hastings Center Report 25 (4):6-15.
    Direct download (2 more)  
     
    My bibliography  
     
    Export citation  
  30. Nancy M. P. King (1992). Transparency in Neonatal Intensive Care. Hastings Center Report 22 (3):18-25.
    Direct download (2 more)  
     
    My bibliography  
     
    Export citation  
  31. Nancy M. P. King (1991). Dying Made Legal: New Challenge for Advance Directives. [REVIEW] HEC Forum 3 (4):187-199.
    Direct download (5 more)  
     
    My bibliography  
     
    Export citation